{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T20:45:43Z","timestamp":1786135543705,"version":"build-2736575974"},"reference-count":117,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["JASN"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:p>\n                    Remarkable progress has been made in the discovery of autoantigens in membranous nephropathy. With increasing testing for membranous antigens in daily practice, it is important to consider the varying strength of associations between certain antigens and underlying conditions. This review explores questions and caveats that arise when assessing results of membranous antigen testing. Specifically, we will discuss: (\n                    <jats:italic toggle=\"yes\">1<\/jats:italic>\n                    ) discrepancy between tissue antigen and clinical scenario, focusing on phospholipase A2 receptor; (\n                    <jats:italic toggle=\"yes\">2<\/jats:italic>\n                    ) one antigen\u2260one clinical condition,\n                    <jats:italic toggle=\"yes\">i.e<\/jats:italic>\n                    ., the heterogeneity of membranous antigens seen in one clinical condition (such as in sarcoidosis), and conversely, heterogeneity of conditions associated with one antigen (such as for neural epidermal growth factor-like 1); (\n                    <jats:italic toggle=\"yes\">3<\/jats:italic>\n                    ) rare presence of multiple membranous-associated antigens in tissue or blood (such as with antiprotocadherin 7); and (\n                    <jats:italic toggle=\"yes\">4<\/jats:italic>\n                    ) lupus membranous nephritis\u2013related antigens and their influence on diagnosis or treatment.\n                  <\/jats:p>","DOI":"10.1681\/asn.0000000769","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T12:07:05Z","timestamp":1748347625000},"page":"1639-1651","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Questions and Caveats in Antigen-Defined Membranous Nephropathy"],"prefix":"10.1681","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4882-6640","authenticated-orcid":false,"given":"Nicole K.","family":"Andeen","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Oregon Health and Science University, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6560-7266","authenticated-orcid":false,"given":"Vanderlene L.","family":"Kung","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Oregon Health and Science University, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8432-2186","authenticated-orcid":false,"given":"Rupali S.","family":"Avasare","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Oregon Health and Science University, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Barbour","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8261-1216","authenticated-orcid":false,"given":"Megan","family":"Griffith","sequence":"additional","affiliation":[{"name":"Department Immunology and Inflammation, Faculty of Medicine, Imperial College, London, United Kingdom"},{"name":"Imperial College Healthcare NHS Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei Lin Z.","family":"Bissonnette","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6490-4290","authenticated-orcid":false,"given":"Candice","family":"Roufosse","sequence":"additional","affiliation":[{"name":"Department Immunology and Inflammation, Centre for Inflammatory Disease, Faculty of Medicine, Imperial College, London, United Kingdom"},{"name":"North West London Pathology, Charing Cross Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"issue":"1","key":"B1-20251209","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med."},{"issue":"11","key":"B2-20251209","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.mayocp.2023.08.006","article-title":"Mayo clinic consensus report on membranous nephropathy: proposal for a novel classification","volume":"98","author":"Sethi","year":"2023","journal-title":"Mayo Clin Proc."},{"issue":"12","key":"B3-20251209","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.2215\/CJN.05480421","article-title":"Noninvasive diagnosis of PLA2R-associated membranous nephropathy: a validation study","volume":"16","author":"Bobart","year":"2021","journal-title":"Clin J Am Soc Nephrol."},{"issue":"4S","key":"B4-20251209","first-page":"S1","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int."},{"issue":"2","key":"B5-20251209","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.kint.2018.10.021","article-title":"Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies","volume":"95","author":"Bobart","year":"2019","journal-title":"Kidney Int."},{"issue":"8","key":"B6-20251209","doi-asserted-by":"crossref","first-page":"e104936","DOI":"10.1371\/journal.pone.0104936","article-title":"The diagnosis accuracy of PLA2R-AB in the diagnosis of idiopathic membranous nephropathy: a meta-analysis","volume":"9","author":"Du","year":"2014","journal-title":"PLoS One."},{"key":"B7-20251209","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/143274","article-title":"Antiphospholipase A(2) receptor autoantibodies: a comparison of three different immunoassays for the diagnosis of idiopathic membranous nephropathy","volume":"2014","author":"Behnert","year":"2014","journal-title":"J Immunol Res."},{"issue":"2","key":"B8-20251209","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.kint.2022.11.004","article-title":"False-positive anti-PLA2R ELISA testing in patients with diabetes mellitus","volume":"103","author":"Caza","year":"2023","journal-title":"Kidney Int."},{"issue":"1","key":"B9-20251209","doi-asserted-by":"crossref","first-page":"16188","DOI":"10.1038\/s41598-021-94921-y","article-title":"Characterization of THSD7A-antibodies not binding to glomerular THSD7A in a patient with diabetes mellitus but no membranous nephropathy","volume":"11","author":"Reinhard","year":"2021","journal-title":"Sci Rep."},{"issue":"5","key":"B10-20251209","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/modpathol.2012.207","article-title":"Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies","volume":"26","author":"Larsen","year":"2013","journal-title":"Mod Pathol."},{"key":"B11-20251209","doi-asserted-by":"crossref","first-page":"8803","DOI":"10.1038\/srep08803","article-title":"Diagnostic accuracy of PLA2R autoantibodies and glomerular staining for the differentiation of idiopathic and secondary membranous nephropathy: an updated meta-analysis","volume":"5","author":"Dai","year":"2015","journal-title":"Sci Rep."},{"issue":"1","key":"B12-20251209","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12882-023-03273-4","article-title":"The value of PLA2R antigen and IgG subclass staining relative to anti-PLA2R seropositivity in the differential diagnosis of membranous nephropathy","volume":"24","author":"Bajcsi","year":"2023","journal-title":"BMC Nephrol."},{"issue":"6","key":"B13-20251209","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1172\/JCI72270","article-title":"Membranous nephropathy: from models to man","volume":"124","author":"Beck","year":"2014","journal-title":"J Clin Invest."},{"issue":"4-5","key":"B14-20251209","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000431331","article-title":"Renal phospholipase A2 receptor in hepatitis B virus-associated membranous nephropathy","volume":"41","author":"Xie","year":"2015","journal-title":"Am J Nephrol."},{"issue":"1","key":"B15-20251209","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1186\/s12882-020-02042-x","article-title":"Membranous nephropathy in patients with HIV: a report of 11 cases","volume":"21","author":"Charu","year":"2020","journal-title":"BMC Nephrol."},{"issue":"3","key":"B16-20251209","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/ckj\/sfaa026","article-title":"Membranous nephropathy associated with viral infection","volume":"14","author":"Nikolopoulou","year":"2021","journal-title":"Clin Kidney J."},{"issue":"6","key":"B17-20251209","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.ekir.2023.03.019","article-title":"Heterogeneity of target antigens in sarcoidosis-associated membranous nephropathy","volume":"8","author":"Zubidat","year":"2023","journal-title":"Kidney Int Rep."},{"issue":"6","key":"B18-20251209","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1093\/ndt\/gfv080","article-title":"Phospholipase A2 receptor and sarcoidosis-associated membranous nephropathy","volume":"30","author":"Stehl\u00e9","year":"2015","journal-title":"Nephrol Dial Transplant."},{"issue":"5","key":"B19-20251209","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1053\/j.ajkd.2020.04.013","article-title":"Podocyte antigen staining to identify distinct phenotypes and outcomes in membranous nephropathy: a retrospective multicenter cohort study","volume":"76","author":"Hanset","year":"2020","journal-title":"Am J Kidney Dis."},{"issue":"6","key":"B20-20251209","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.semnephrol.2010.09.011","article-title":"Membranous nephropathy and malignancy","volume":"30","author":"Beck","year":"2010","journal-title":"Semin Nephrol."},{"issue":"1","key":"B21-20251209","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1046\/j.1523-1755.1999.00548.x","article-title":"Paraneoplastic glomerulopathies: new insights into an old entity","volume":"56","author":"Ronco","year":"1999","journal-title":"Kidney Int."},{"issue":"4","key":"B22-20251209","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/ki.1986.209","article-title":"Neoplasia and glomerular injury","volume":"30","author":"Alpers","year":"1986","journal-title":"Kidney Int."},{"issue":"6","key":"B23-20251209","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1053\/j.ajkd.2013.07.019","article-title":"Anti-phospholipase A2 receptor antibodies and malignancy in membranous nephropathy","volume":"62","author":"Timmermans","year":"2013","journal-title":"Am J Kidney Dis."},{"issue":"3","key":"B24-20251209","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1681\/ASN.0000000000000061","article-title":"Membranous nephropathy in syphilis is associated with neuron-derived neurotrophic factor","volume":"34","author":"Sethi","year":"2023","journal-title":"J Am Soc Nephrol."},{"issue":"7","key":"B25-20251209","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1093\/ckj\/sfab057","article-title":"The immunohistological profile of membranous nephropathy associated with syphilis infection","volume":"14","author":"Wanderley","year":"2021","journal-title":"Clin Kidney J."},{"issue":"2","key":"B26-20251209","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ekir.2023.11.021","article-title":"Target antigens of membranous nephropathy with syphilis infection","volume":"9","author":"Zhang","year":"2024","journal-title":"Kidney Int Rep."},{"issue":"5","key":"B27-20251209","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1681\/ASN.2021111488","article-title":"Hematopoietic stem cell transplant-membranous nephropathy is associated with protocadherin FAT1","volume":"33","author":"Sethi","year":"2022","journal-title":"J Am Soc Nephrol."},{"issue":"7","key":"B28-20251209","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1016\/j.ekir.2021.04.033","article-title":"NELL1-associated membranous glomerulopathy after hematopoietic stem cell transplantation","volume":"6","author":"Kudose","year":"2021","journal-title":"Kidney Int Rep."},{"issue":"2","key":"B29-20251209","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1016\/j.ekir.2024.11.218","article-title":"WCN25-3229 breaking disease barriers: a case of ANTI-PLA2R positive membranous nephropathy following allogeneic stem cell transplantation","volume":"10","author":"Debnath","year":"2025","journal-title":"Kidney Int Rep."},{"issue":"6","key":"B30-20251209","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1053\/j.ajkd.2021.07.021","article-title":"Membranous nephropathy with extensive tubular basement membrane deposits following allogeneic hematopoietic cell transplant: a report of 5 cases","volume":"79","author":"Nasr","year":"2022","journal-title":"Am J Kidney Dis."},{"issue":"2","key":"B31-20251209","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2169\/internalmedicine.9655-22","article-title":"Chronic graft-versus-host disease-associated membranous nephropathy following bone marrow transplantation, successfully treated with rituximab","volume":"62","author":"Sakai","year":"2023","journal-title":"Intern Med."},{"key":"B32-20251209","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.humpath.2015.12.005","article-title":"Clinicopathological analysis of allogeneic hematopoietic stem cell transplantation-related membranous glomerulonephritis","volume":"50","author":"Hiramatsu","year":"2016","journal-title":"Hum Pathol."},{"issue":"10366","key":"B34-20251209","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1016\/S0140-6736(22)02039-6","article-title":"Bacterial infection possibly causing autoimmunity: Tropheryma whipplei and membranous nephropathy","volume":"400","author":"Wiech","year":"2022","journal-title":"Lancet."},{"issue":"1","key":"B35-20251209","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/s12882-022-02871-y","article-title":"Favorable outcome in PLA2R positive HBV-associated membranous nephropathy","volume":"23","author":"Chen","year":"2022","journal-title":"BMC Nephrol."},{"issue":"1","key":"B36-20251209","doi-asserted-by":"crossref","first-page":"20981","DOI":"10.1038\/s41598-024-72082-y","article-title":"Efficacy and safety of rituximab in patients with PLA2R associated membranous nephropathy and resolved HCV infection","volume":"14","author":"Li","year":"2024","journal-title":"Sci Rep."},{"key":"B37-20251209","doi-asserted-by":"crossref","first-page":"111327","DOI":"10.1016\/j.intimp.2023.111327","article-title":"Effect of rituximab in patients with PLA2R-associated membranous nephropathy and malignancy","volume":"126","author":"Guo","year":"2024","journal-title":"Int Immunopharmacol."},{"key":"B38-20251209","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.3389\/fimmu.2018.03035","article-title":"Antigen-specific IgG subclasses in primary and malignancy-associated membranous nephropathy","volume":"9","author":"von Haxthausen","year":"2018","journal-title":"Front Immunol."},{"issue":"4","key":"B39-20251209","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.ekir.2020.12.035","article-title":"Rituximab in membranous nephropathy","volume":"6","author":"Gauckler","year":"2021","journal-title":"Kidney Int Rep."},{"issue":"4","key":"B40-20251209","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.kint.2020.10.014","article-title":"The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy","volume":"99","author":"Fern\u00e1ndez-Ju\u00e1rez","year":"2021","journal-title":"Kidney Int."},{"issue":"1","key":"B41-20251209","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N Engl J Med."},{"issue":"6","key":"B42-20251209","doi-asserted-by":"crossref","first-page":"886","DOI":"10.2215\/CJN.09000819","article-title":"Screening for cancer in patients with glomerular diseases","volume":"15","author":"Plaisier","year":"2020","journal-title":"Clin J Am Soc Nephrol."},{"issue":"1","key":"B43-20251209","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ekir.2024.10.012","article-title":"De novo membranous nephropathy in renal allografts is associated with protocadherin FAT1","volume":"10","author":"Al-Rabadi","year":"2025","journal-title":"Kidney Int Rep."},{"issue":"5","key":"B44-20251209","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.kint.2024.08.009","article-title":"FAT1 is a target antigen in a subset of de novo allograft membranous nephropathy associated with antibody mediated rejection","volume":"106","author":"Sethi","year":"2024","journal-title":"Kidney Int."},{"issue":"5","key":"B46-20251209","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.ekir.2024.02.1401","article-title":"Characteristics and outcomes of NELL1 membranous nephropathy in lipoic acid users and nonusers","volume":"9","author":"Avasare","year":"2024","journal-title":"Kidney Int Rep."},{"issue":"6","key":"B47-20251209","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.kint.2021.10.010","article-title":"Lipoic acid supplementation associated with neural epidermal growth factor-like 1 (NELL1)-associated membranous nephropathy","volume":"100","author":"Spain","year":"2021","journal-title":"Kidney Int."},{"key":"B48-20251209","article-title":"Bucillamine use for rheumatoid arthritis and type 2 diabetes mellitus are associated with neural epidermal growth factor-like 1 (NELL1)-associated membranous nephropathy","author":"Tsuji","year":"2022","journal-title":"medRxiv."},{"issue":"4","key":"B49-20251209","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.ekir.2022.12.026","article-title":"Neural epidermal growth factor-like 1-positive membranous nephropathy with rheumatoid arthritis","volume":"8","author":"Miyazaki","year":"2023","journal-title":"Kidney Int Rep."},{"issue":"8","key":"B50-20251209","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1016\/j.ekir.2023.05.032","article-title":"Adding cases to the study of bucillamine-associated neural epidermal growth factor-like1-positive membranous nephropathy","volume":"8","author":"Takahashi-Kobayashi","year":"2023","journal-title":"Kidney Int Rep."},{"issue":"8","key":"B51-20251209","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.ekir.2023.05.023","article-title":"Segmental NELL-1 membranous nephropathy complicating tiopronin therapy","volume":"8","author":"Santoriello","year":"2023","journal-title":"Kidney Int Rep."},{"issue":"6","key":"B52-20251209","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/j.kint.2022.09.001","article-title":"Traditional indigenous medicines are an etiologic consideration for NELL1-positive membranous nephropathy","volume":"102","author":"Kurien","year":"2022","journal-title":"Kidney Int."},{"key":"B53-20251209","doi-asserted-by":"crossref","first-page":"1323432","DOI":"10.3389\/fneph.2024.1323432","article-title":"NELL1 membranous nephropathy: clinical associations provide mechanistic clues","volume":"4","author":"Andeen","year":"2024","journal-title":"Front Nephrol."},{"issue":"5","key":"B54-20251209","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/15563650.2023.2188141","article-title":"Mercury-associated neural epidermal growth factor-like 1 protein (NELL-1) positive membranous nephropathy after use of skin lightening creams","volume":"61","author":"Sultan","year":"2023","journal-title":"Clin Toxicol (Phila)."},{"issue":"1","key":"B55-20251209","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.kint.2019.09.014","article-title":"Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy","volume":"97","author":"Sethi","year":"2020","journal-title":"Kidney Int."},{"issue":"20","key":"B56-20251209","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMc1511702","article-title":"A mechanism for cancer-associated membranous nephropathy","volume":"374","author":"Hoxha","year":"2016","journal-title":"N Engl J Med."},{"issue":"4","key":"B57-20251209","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/gcc.22440","article-title":"THSD7A expression in human cancer","volume":"56","author":"Stahl","year":"2017","journal-title":"Genes Chromosomes Cancer."},{"issue":"4","key":"B59-20251209","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/modpathol.2016.32","article-title":"THSD7A staining of membranous glomerulopathy in clinical practice reveals cases with dual autoantibody positivity","volume":"29","author":"Larsen","year":"2016","journal-title":"Mod Pathol."},{"issue":"3","key":"B60-20251209","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.kint.2018.10.024","article-title":"Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy","volume":"95","author":"Zaghrini","year":"2019","journal-title":"Kidney Int."},{"issue":"10","key":"B61-20251209","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.2215\/CJN.01460217","article-title":"Circulating antibodies against thrombospondin type-I domain-containing 7A in Chinese patients with idiopathic membranous nephropathy","volume":"12","author":"Wang","year":"2017","journal-title":"Clin J Am Soc Nephrol."},{"issue":"6","key":"B62-20251209","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00428-019-02558-0","article-title":"Clinicopathological characteristics of thrombospondin type 1 domain-containing 7A-associated membranous nephropathy","volume":"474","author":"Hara","year":"2019","journal-title":"Virchows Arch."},{"key":"B63-20251209","doi-asserted-by":"crossref","first-page":"102308","DOI":"10.1016\/j.jaut.2019.102308","article-title":"Autoantigens PLA2R and THSD7A in membranous nephropathy share a common epitope motif in the N-terminal domain","volume":"106","author":"Fresquet","year":"2020","journal-title":"J Autoimmun."},{"issue":"5","key":"B64-20251209","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2215\/CJN.11860720","article-title":"Neural epidermal growth factor-like 1 protein-positive membranous nephropathy in Chinese patients","volume":"16","author":"Wang","year":"2021","journal-title":"Clin J Am Soc Nephrol."},{"issue":"4","key":"B65-20251209","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000525541","article-title":"NELL1-Positive HIV-associated lupus-like membranous nephropathy with spontaneous remission","volume":"2","author":"Dinesh","year":"2022","journal-title":"Glomerular Dis."},{"issue":"5","key":"B66-20251209","doi-asserted-by":"crossref","first-page":"100625","DOI":"10.1016\/j.xkme.2023.100625","article-title":"Anti-PLA(2)R antibody development during NELL1-associated membranous glomerulonephritis treatment: a case report","volume":"5","author":"Inoue","year":"2023","journal-title":"Kidney Med."},{"issue":"3","key":"B67-20251209","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.ekir.2022.12.018","article-title":"Pembrolizumab-associated nerve epidermal growth factor-like 1 membranous nephropathy","volume":"8","author":"Nimkar","year":"2023","journal-title":"Kidney Int Rep."},{"issue":"2","key":"B68-20251209","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1681\/ASN.2020071082","article-title":"New \u02bbantigens\u2019 in membranous nephropathy","volume":"32","author":"Sethi","year":"2021","journal-title":"J Am Soc Nephrol."},{"issue":"12","key":"B69-20251209","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1007\/s00467-022-05503-7","article-title":"Clinicopathologic features of non-lupus membranous nephropathy in a pediatric population","volume":"37","author":"Miller","year":"2022","journal-title":"Pediatr Nephrol."},{"issue":"5","key":"B70-20251209","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.kint.2020.05.030","article-title":"Semaphorin 3B-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients","volume":"98","author":"Sethi","year":"2020","journal-title":"Kidney Int."},{"issue":"3","key":"B71-20251209","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1681\/ASN.2021101323","article-title":"Recurrence of anti-semaphorin 3B-mediated membranous nephropathy after kidney transplantation","volume":"33","author":"Fila","year":"2022","journal-title":"J Am Soc Nephrol."},{"issue":"10","key":"B72-20251209","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/j.ekir.2023.07.005","article-title":"The antigenic landscape of pediatric membranous nephropathy","volume":"8","author":"Kurien","year":"2023","journal-title":"Kidney Int Rep."},{"issue":"1","key":"B73-20251209","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00467-023-06085-8","article-title":"A child with semaphorin 3b-associated membranous nephropathy effectively treated with obinutuzumab after rituximab resistance","volume":"39","author":"Conversano","year":"2024","journal-title":"Pediatr Nephrol."},{"issue":"1","key":"B74-20251209","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.kint.2024.10.012","article-title":"PCDH7-antibodies and PCDH7 immune deposits are mostly found in patients with PLA2R1- or NELL1-associated membranous nephropathy","volume":"107","author":"Machalitza","year":"2025","journal-title":"Kidney Int."},{"issue":"5","key":"B75-20251209","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1681\/ASN.2020081165","article-title":"Protocadherin 7-associated membranous nephropathy","volume":"32","author":"Sethi","year":"2021","journal-title":"J Am Soc Nephrol."},{"issue":"1S","key":"B76-20251209","first-page":"S1","article-title":"KDIGO 2024 clinical practice guideline for the management of LUPUS NEPHRITIS","volume":"105","year":"2024","journal-title":"Kidney Int."},{"issue":"3","key":"B77-20251209","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1681\/ASN.2020081181","article-title":"In patients with membranous lupus nephritis, exostosin-positivity and exostosin-negativity represent two different phenotypes","volume":"32","author":"Ravindran","year":"2021","journal-title":"J Am Soc Nephrol."},{"issue":"5","key":"B78-20251209","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/10935266241237656","article-title":"Diagnostic challenges and emerging pathogeneses of selected glomerulopathies","volume":"27","author":"Andeen","year":"2024","journal-title":"Pediatr Dev Pathol."},{"issue":"2","key":"B79-20251209","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1093\/ndt\/gfac058","article-title":"EXT1 and NCAM1-associated membranous lupus nephritis in a cohort of patients undergoing repeat kidney biopsies","volume":"38","author":"Miller","year":"2023","journal-title":"Nephrol Dial Transplant."},{"issue":"2","key":"B80-20251209","doi-asserted-by":"crossref","first-page":"e0281726","DOI":"10.1371\/journal.pone.0281726","article-title":"Can use of the serum anti-PLA2R antibody negate the need for a renal biopsy in primary membranous nephropathy?","volume":"18","author":"Ragy","year":"2023","journal-title":"PLoS One."},{"issue":"2","key":"B82-20251209","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ekir.2017.10.013","article-title":"The role of PLA2R antibody in treatment of membranous nephropathy","volume":"3","author":"Dahan","year":"2018","journal-title":"Kidney Int Rep."},{"issue":"6","key":"B83-20251209","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.2215\/CJN.07210810","article-title":"Anti-phospholipase A\u2082 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy","volume":"6","author":"Hofstra","year":"2011","journal-title":"Clin J Am Soc Nephrol."},{"issue":"6","key":"B84-20251209","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1681\/ASN.2013040430","article-title":"Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy","volume":"25","author":"Hoxha","year":"2014","journal-title":"J Am Soc Nephrol."},{"issue":"3","key":"B85-20251209","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1159\/000440983","article-title":"Anti-phospholipase A2 receptor antibody as prognostic indicator in idiopathic membranous nephropathy","volume":"42","author":"Kim","year":"2015","journal-title":"Am J Nephrol."},{"issue":"1","key":"B86-20251209","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1681\/ASN.2016040449","article-title":"Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up","volume":"28","author":"Dahan","year":"2017","journal-title":"J Am Soc Nephrol."},{"issue":"10","key":"B87-20251209","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.2215\/CJN.0000000000000237","article-title":"Anti-PLA2R antibody levels and clinical risk factors for treatment nonresponse in membranous nephropathy","volume":"18","author":"Barbour","year":"2023","journal-title":"Clin J Am Soc Nephrol."},{"issue":"3","key":"B88-20251209","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/ckj\/sfx128","article-title":"The utility of phospholipase A2 receptor autoantibody in membranous nephropathy after kidney transplantation","volume":"11","author":"Xipell","year":"2018","journal-title":"Clin Kidney J."},{"issue":"6","key":"B89-20251209","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.ajt.2024.01.036","article-title":"Recurrence of membranous nephropathy after kidney transplantation: a multicenter retrospective cohort study","volume":"24","author":"Hullekes","year":"2024","journal-title":"Am J Transplant."},{"issue":"12","key":"B90-20251209","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1016\/j.ekir.2024.09.012","article-title":"Anti phospholipase A2 receptor 1 antibodies and membranous nephropathy recurrence after kidney transplantation","volume":"9","author":"Cremoni","year":"2024","journal-title":"Kidney Int Rep."},{"issue":"1","key":"B91-20251209","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1681\/ASN.2013020185","article-title":"Long-term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategy","volume":"25","author":"van den Brand","year":"2014","journal-title":"J Am Soc Nephrol."},{"issue":"11","key":"B92-20251209","first-page":"CD004293","article-title":"Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome","volume":"11","author":"von Groote","year":"2021","journal-title":"Cochrane Database Syst Rev."},{"issue":"10","key":"B93-20251209","first-page":"CD004293","article-title":"Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome","volume":"2014","author":"Chen","year":"2014","journal-title":"Cochrane Database Syst Rev."},{"issue":"10","key":"B94-20251209","first-page":"CD004293","volume":"2014","author":"Chen","year":"2014"},{"issue":"2","key":"B95-20251209","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s40620-020-00888-w","article-title":"Diagnostic accuracy of anti-phospholipase A2 receptor (PLA2R) antibodies in idiopathic membranous nephropathy: an Italian experience","volume":"34","author":"Porcelli","year":"2021","journal-title":"J Nephrol."},{"issue":"2-3","key":"B96-20251209","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000521836","article-title":"Optimal value for serum anti-PLA2R antibody in primary membranous nephropathy: a multicenter observational study","volume":"53","author":"Chen","year":"2022","journal-title":"Am J Nephrol."},{"issue":"12","key":"B97-20251209","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.3390\/jcm10122624","article-title":"Clinical phenotypes and predictors of remission in primary membranous nephropathy","volume":"10","author":"Jurubi\u0163\u0103","year":"2021","journal-title":"J Clin Med."},{"issue":"8","key":"B98-20251209","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/j.ekir.2023.05.019","article-title":"PLA2R antibody does not outperform conventional clinical markers in predicting outcomes in membranous nephropathy","volume":"8","author":"Ragy","year":"2023","journal-title":"Kidney Int Rep."},{"issue":"3","key":"B99-20251209","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/ckj\/sfac237","article-title":"The many faces of NELL1 MN","volume":"16","author":"Sethi","year":"2023","journal-title":"Clin Kidney J."},{"issue":"4","key":"B100-20251209","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.kint.2020.07.039","article-title":"NELL1 is a target antigen in malignancy-associated membranous nephropathy","volume":"99","author":"Caza","year":"2021","journal-title":"Kidney Int."},{"issue":"10S","key":"B101-20251209","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1681\/ASN.20244npc2smf","article-title":"Detection and characterization of NELL1 autoantibodies in NELL1-positive membranous nephropathy","volume":"35","author":"Caza","year":"2024","journal-title":"J Am Soc Nephrol."},{"issue":"8","key":"B102-20251209","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1159\/000528078","article-title":"Neuronal proteins as antigenic targets in membranous nephropathy","volume":"147","author":"Al-Rabadi","year":"2023","journal-title":"Nephron."},{"issue":"1","key":"B103-20251209","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41572-021-00303-z","article-title":"Membranous nephropathy","volume":"7","author":"Ronco","year":"2021","journal-title":"Nat Rev Dis Primers."},{"issue":"7","key":"B104-20251209","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/s41581-022-00564-1","article-title":"Membranous nephropathy: new pathogenic mechanisms and their clinical implications","volume":"18","author":"Hoxha","year":"2022","journal-title":"Nat Rev Nephrol."},{"issue":"3","key":"B105-20251209","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.kint.2023.01.001","article-title":"Discovery of seven novel putative antigens in membranous nephropathy and membranous lupus nephritis identified by mass spectrometry","volume":"103","author":"Caza","year":"2023","journal-title":"Kidney Int."},{"issue":"6","key":"B106-20251209","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.kint.2021.08.014","article-title":"Contactin-1 is a novel target antigen in membranous nephropathy associated with chronic inflammatory demyelinating polyneuropathy","volume":"100","author":"Le Quintrec","year":"2021","journal-title":"Kidney Int."},{"issue":"2","key":"B107-20251209","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1053\/j.ajkd.2021.08.025","article-title":"Contactin 1, a potential new antigen target in membranous nephropathy: a case report","volume":"80","author":"Santoro","year":"2022","journal-title":"Am J Kidney Dis."},{"issue":"10","key":"B108-20251209","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1681\/ASN.2022050608","article-title":"Netrin G1 is a novel target antigen in primary membranous nephropathy","volume":"33","author":"Reinhard","year":"2022","journal-title":"J Am Soc Nephrol."},{"issue":"8","key":"B109-20251209","doi-asserted-by":"crossref","first-page":"104698","DOI":"10.1016\/j.isci.2022.104698","article-title":"Estimating the number of diseases - the concept of rare, ultra-rare, and hyper-rare","volume":"25","author":"Smith","year":"2022","journal-title":"iScience."},{"issue":"5","key":"B110-20251209","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/PAS.0000000000000605","article-title":"IgG subclass staining in routine renal biopsy material","volume":"40","author":"Hemminger","year":"2016","journal-title":"Am J Surg Pathol."},{"issue":"6","key":"B111-20251209","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1681\/ASN.2010090967","article-title":"Anti-phospholipase A2 receptor antibody in membranous nephropathy","volume":"22","author":"Qin","year":"2011","journal-title":"J Am Soc Nephrol."},{"issue":"6","key":"B112-20251209","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.kint.2023.06.032","article-title":"Mayo Clinic consensus report on membranous nephropathy: proposal for a novel classification","volume":"104","author":"Sethi","year":"2023","journal-title":"Kidney Int."},{"issue":"1","key":"B113-20251209","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.kint.2020.06.014","article-title":"The clinicopathologic spectrum of segmental membranous glomerulopathy","volume":"99","author":"Kudose","year":"2021","journal-title":"Kidney Int."},{"issue":"6","key":"B114-20251209","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1159\/000533294","article-title":"Segmental membranous glomerulopathy in adults","volume":"9","author":"Zhu","year":"2023","journal-title":"Kidney Dis."},{"issue":"4","key":"B115-20251209","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.ajt.2024.11.026","article-title":"Neural epidermal growth factor-like 1 protein-positive membranous nephropathy in renal allografts: a series of 6 patients","volume":"25","author":"Kenan","year":"2025","journal-title":"Am J Transplant."},{"issue":"8","key":"B116-20251209","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.34067\/KID.0001492021","article-title":"Transforming growth factor beta receptor 3 (TGFBR3)-Associated membranous nephropathy","volume":"2","author":"Caza","year":"2021","journal-title":"Kidney360."},{"issue":"6","key":"B117-20251209","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1681\/ASN.2018080852","article-title":"Exostosin 1\/exostosin 2-associated membranous nephropathy","volume":"30","author":"Sethi","year":"2019","journal-title":"J Am Soc Nephrol."},{"issue":"1","key":"B118-20251209","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.kint.2020.09.016","article-title":"Neural cell adhesion molecule 1 is a novel autoantigen in membranous lupus nephritis","volume":"100","author":"Caza","year":"2021","journal-title":"Kidney Int."},{"issue":"1","key":"B119-20251209","doi-asserted-by":"crossref","first-page":"2355353","DOI":"10.1080\/0886022X.2024.2355353","article-title":"Prevalence and prognosis of malignancy in THSD7A-associated membranous nephropathy: a systematic literature review and clinical case study","volume":"46","author":"Xu","year":"2024","journal-title":"Ren Fail."},{"issue":"1","key":"B120-20251209","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1080\/0886022X.2018.1456457","article-title":"An update on clinical significance of use of THSD7A in diagnosing idiopathic membranous nephropathy: a systematic review and meta-analysis of THSD7A in IMN","volume":"40","author":"Ren","year":"2018","journal-title":"Ren Fail."},{"issue":"2","key":"B121-20251209","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.kint.2023.04.006","article-title":"Proprotein convertase subtilisin\/kexin type 6 (PCSK6) is a likely antigenic target in membranous nephropathy and nonsteroidal anti-inflammatory drug use","volume":"104","author":"Sethi","year":"2023","journal-title":"Kidney Int."}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.0000000769","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:45:27Z","timestamp":1786131927000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.0000000769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":117,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.0000000769","relation":{},"ISSN":["1046-6673","1533-3450"],"issn-type":[{"value":"1046-6673","type":"print"},{"value":"1533-3450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]}}}